Sumitomo Pharma Receives FDA Orphan Drug Designation for Retinitis Pigmentosa Treatment

Sumitomo Pharma America has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DSP-3077, an investigational cell therapy for the treatment of retinitis pigmentosa (RP).

The FDA's Orphan Drug Designation is granted to therapies intended to treat rare diseases that affect fewer than 200,000 people in the United States. This special status provides several benefits to encourage pharmaceutical companies to develop treatments for conditions that might otherwise be overlooked due to their limited market size.

Benefits of orphan drug designation include tax credits for clinical trial costs, exemption from FDA user fees, and the potential for seven years of market exclusivity if the drug is eventually approved. These incentives help offset the significant costs and risks associated with developing treatments for rare diseases.

Retinitis pigmentosa is a rare, progressive hereditary blinding condition affecting approximately 1 in 4,000 individuals, with very limited or, in many cases, no approved therapies available. RP first results in loss of night and peripheral vision, but ultimately affects central vision in most cases.

DSP-3077 is an investigational therapy delivering retinal sheets into the eyes of patients with RP and is currently being evaluated in a Phase 1/2 clinical study. The sheets are derived from 3D retina-like structures grown in the lab. This innovative approach represents a form of regenerative medicine, using laboratory-grown retinal tissue to potentially replace damaged photoreceptors in patients' eyes.

Foundation Fighting Blindness has long supported research into retinitis pigmentosa and continues to fund innovative approaches across multiple therapeutic strategies—from gene therapies to regenerative medicine treatments like DSP-3077—ensuring that diverse approaches are being pursued to help patients with RP.